2336. Resistance Mechanisms and Factors associated with CTX-M-9 group Extended-Spectrum Beta-Lactamase (ESBL)- producing Enterobacteriaceae Infections in Children
Session: Poster Abstract Session: Pediatric Bacterial Infections
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • CTX-M-9 IDWeek Presentation for upload.jpg (762.3 kB)
  • Background: There is an increasing incidence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae (Ent) infections in children. However, most studies focus only on CTX-M-1 group (CTX-M-15). We sought to define the epidemiology of the CTX-M-9 group (CTX-M-9) producing Ent infections in children to devise more effective treatment and prevention strategies.

    Methods: A case-control study of children (0-21 y), cared for by 3 Chicago area hospitals during 2011-16, was performed. Cases were 44 children diagnosed with 3rd generation cephalosporin (3GC) resistant and/or carbapenem-resistant (CR) Ent infections who had CTX-M-9 genes accounting for beta-lactam resistance. PCR amplification, DNA sequencing, and DNA microarray analysis (Check-Points®) assessed for bla genes. MLST, rep-PCR and phylogenetic analysis were also performed. Controls were 135 children with 3GC and carbapenem susceptible Ent infections matched by age range and hospital. Demographics; comorbidities; device, antibiotic, and healthcare exposures; and the impact of location of patient residence were evaluated. Race categories were white, black, Hispanic, and other. Stratified analysis and multivariable logistic regression were used to explore associations between predictors and CTX-M-9 infection. Data were analyzed in SAS 9.4.

    Results: The median age of cases was 4.1 years. The predominant organism (39/44, 89%) was E. coli of virulent phylogroups B2 (41%) and D (59%). MLST analysis revealed that this collection of strains was polyclonal.

    On multivariable analysis, children with CTX-M-9 Ent infections were more likely to be diagnosed in an outpatient clinic (OR 4.5), have E. coli infection (OR 7.0), and be of race “other” (OR 7.6) vs. controls. Residents of South Chicago were 6.7 times more likely to have a CTX-M-9 Ent infection than controls; while residence in Northwest Chicago was associated with a 81% decreased risk. Significant differences in other demographics, comorbidities, invasive devices, antibiotic use, or recent healthcare were not found.

    Conclusion: We observed striking regional differences in occurrence of CTX-M-9 producing Ent, suggesting that environmental influences and plasmid transfer may contribute to acquisition. It is worrisome that a large number of ESBL Ent strains bearing CTX-M ESBLs circulate in the community among children.

    Rachel L. Medernach, M.D.1, T. Nicholas Domitrovic, MS2, Jared R. Rispens, M.D.3, Andrea M. Hujer, BS4, Nadia K. Qureshi, MD5, Steven H. Marshall, MS6, David C. Nguyen, MD7, Susan D. Rudin, B.S.8, Xiaotian Zheng, MD, PhD9, Robert A. Weinstein, MD, FIDSA, FSHEA10, Robert A. Bonomo, MD11,12 and Latania K. Logan, MD, MSc2,13,14,15, (1)Rush University Medical Center, Chicago, IL, (2)Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH, (3)Internal Medicine and Pediatrics, Rush University Medical Center, Chicago, IL, (4)Louis Stokes Cleveland VA Medical Center, Cleveland, OH, (5)Pediatrics, Loyola University Medical Center, Maywood, IL, (6)Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, (7)Departments of Internal Medicine and Pediatrics, Rush University Medical Center, Chicago, IL, (8)Research Service, VA Cleveland Medical Center, Cleveland, OH, (9)Children's Memorial Hospital, Chicago, IL, (10)Division of Infectious Diseases, Rush University Medical Center, Chicago, IL, (11)Research, Louis Stokes Cleveland Veteran's Affairs Medical Center, Cleveland, OH, (12)Medicine, Case Western Reserve University, Cleveland, OH, (13)Pediatrics, Rush University Medical Center, Chicago, IL, (14)Rush Medical College, Chicago, IL, (15)John Stroger Hospital of Cook County, Chicago, IL

    Disclosures:

    R. L. Medernach, None

    T. N. Domitrovic, None

    J. R. Rispens, None

    A. M. Hujer, None

    N. K. Qureshi, None

    S. H. Marshall, None

    D. C. Nguyen, None

    S. D. Rudin, None

    X. Zheng, None

    R. A. Weinstein, None

    R. A. Bonomo, None

    L. K. Logan, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.